• US: +1-408-610-2300
  • Toll Free: +1-866-831-4085
  • Login / Register
Epilepsy Drugs Market Size, Share, 2013-2024 | Global Industry Report

Epilepsy Drugs Market Size & Forecast Report, 2013 - 2024

Report ID: MN17617575  |  Published: July 2016  |  No of Pages: 91
Format: Electronic (PDF)  |  Industry: Pharmaceuticals  |  Publisher: Grand View Research

The global Epilepsy Drugs Market is anticipated to rise at a staggering CAGR in the forthcoming period. Epilepsy drugs have pharmacokinetic properties and are administered to children, adults, and adolescents. Carbamazepine is applicable for focal seizures with strong properties of inducing and enables development of milder tolerance level that could be increased weekly.

Epilepsy drugs market is highly driven by rise in cases of stroke, brain tumors, and brain injury. Antiepileptic drugs are prescribed due to the rising demands for treatment for epilepsy. Adoption of novel approach by manufacturers for production of therapeutic drugs also contributes to the market growth in the forecast period.

Change in lifestyle and increase in geriatric population with unmet medical needs along with rise in awareness is expected to trigger the market growth in the near future. However, rise in demand for generic drugs and availability of cheaper substitutes are likely to hinder the market growth in the forecast period.

On the basis of generation, the epilepsy drugs market is segmented as first generation epileptic drugs, second generation epileptic drugs, and pipeline drugs. Pipeline drugs hold a significant market share in the forecast period due to their enhanced efficiency and efficacy.

Geographical segmentation for epilepsy drugs industry includes North America, South America, Europe, Asia-Pacific, Middle East and Africa. North America is a huge market exhibiting higher potential in terms of diagnosis and treatments coupled with rise in prevalence of epilepsy since it has affected a major population in the United States.

Asia-Pacific regions have also registered a remarkable growth in the forecast period due to high prevalence of epilepsy in several parts of the region. Availability of drugs and treatment through novel mechanisms are some factors driving the market growth for APAC. Latin America is a huge market for epilepsy drugs that encompasses significant healthcare expenditure along with higher prevalence of epileptic cases in the region. The key players in the epilepsy drugs market include Sanofi S.A., UCB Pharma Ltd, Valeant Pharmaceuticals, Pfizer Inc, Johnson & Johnson Co, Abbott Laboratories Inc, Novartis AG, GlaxoSmithKline PLC, CephalonInc, and SunovionPharamceuticals.

Market Segment:

Global Epilepsy Drug market (Revenue, USD Million, 2013 - 2024)
    • First generation anti-epileptic drug
    • Second generation anti-epileptic drug
    • Third generation anti-epileptic drug

Epilepsy Drugs Regional Outlook (Revenue, USD Million, 2013 - 2024)
    • North America
        • U.S.
        • Canada
    • Europe
        • UK
        • Germany
    • Asia Pacific
        • India
        • China
    • Latin America
        • Brazil
    • MEA
        • South Africa

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service
  • 100% Secure Payments
  • Our Promise
  • 100% Service Assurance
  • Market Monitoring
  • Service Flexibility
  • 24X5 Care available